The Danish drugmaker released late-stage data showing that the upcoming injection CagriSema failed to match the weight loss of Eli Lilly’s Zepbound.

Novo Nordisk’s study showing a new drug wasn’t as good as a rival’s led one sell-side analyst to downgrade the stock for the first time in five years.

Eli Lilly (LLY) has announced the expansion of its pharmaceutical pipeline, driven by positive trial data and a new licensing agreement.

Novo Nordisk's shares experienced a significant drop after its new obesity drug failed to outperform Eli Lilly's Zepbound in clinical trials.

Eli Lilly is highlighted as a powerful company in the weight-loss and diabetes sectors, recommended as a hold through market downturns.

Cagrisema viser et lavere vægttab end Eli Lillys aktive stof tirzepatid i et nyt studie. Novo-aktien falder til laveste niveau i fem år.

Eli Lilly has announced a landmark trial demonstrating a major breakthrough with its Taltz-Zepbound drug combination for treating both psoriasis and obesity.

Eli Lilly's experimental cancer drug has shown promise in reducing the risk of recurrence in patients with early-stage lung cancer.

The initial excitement surrounding GLP-1 weight loss drugs provides insights into current market dynamics, with connections drawn to jet fuel and software sell-offs.

Investors are advised to keep an eye on Shopify, Eli Lilly, General Mills, and Norwegian Cruise Line Holdings as key stocks to watch on Tuesday.

Eli Lilly has delivered positive news for investors, with implications that reach beyond its well-known weight-loss drug portfolio.

Danish group is struggling to compete with rival Eli Lilly

Eli Lilly’s Zepbound Gets FDA OK for Multi-Dose Pen  The Wall Street Journal

Barclays has begun its coverage of Eli Lilly (LLY), expressing a positive outlook due to the company's robust standing in the obesity treatment market.

Eli Lilly's stock saw a notable increase, with reasons for the sudden pop being explored.

Novo Nordisk's new weight loss injection has not performed as well as a rival drug from Eli Lilly in a recent clinical trial, causing a drop in its stock.

President Trump is raising his threatened global tariff to 15%, and Eli Lilly triumphs over obesity rival Novo Nordisk once again.

Novo Nordisk shares were under pressure on Monday as the struggling Danish pharmaceutical said a head-to-head study found a drug in development didn’t cut as much weight as an Eli Lilly product.

Eli Lilly (LLY) is reportedly expanding its pharmaceutical pipeline through a new agreement involving Clazakizumab, as reported by Reuters.

Jim Cramer shares his insights on Eli Lilly (LLY) and the growing market for weight loss drugs.

CSL has entered into a licensing agreement with Eli Lilly for clazakizumab, a treatment for kidney disease.

Eli Lilly is eyeing India as a global export hub for its Mounjaro drug, driven by surging sales.

The weight-loss drug market is rapidly expanding globally, with a shift from injections to pills and intense competition between pharmaceutical giants like Novo Nordisk and Eli Lilly. Regulatory scrutiny is also impacting new product offerings in this lucrative sector.

Eli Lilly's stock declined after its competitor, Novo Nordisk, announced plans to reduce the list prices for its GLP-1 class of drugs.

Zacks Market Edge provides highlights and analysis for several companies including MasTec, Caterpillar, Walmart, Eli Lilly, and Howmet Aerospace.

Eli Lilly's shares surged after another win against rival Novo Nordisk, further solidifying its lead in the competitive obesity drug market.

Zacks Market Edge provides insights and analysis on several companies, including MasTec, Caterpillar, Walmart, Eli Lilly, and Howmet Aerospace.

Novo Nordisk's stock dropped significantly after new data showed its experimental weight-loss drug Cagrisema was less effective than Eli Lilly's tirzepatide.

Eli Lilly has unveiled long-term data regarding its drug Omvoh, specifically for the treatment of Crohn's disease.

Eli Lilly and Company (LLY) stock has risen due to the expansion of Medicare coverage for GLP-1 weight loss drugs, which has alleviated pricing concerns.

An analyst suggests Eli Lilly stock is a strong buy-and-hold investment, citing reasons to never sell.

Eli Lilly is making a significant $1 billion investment in artificial intelligence, aiming to revolutionize drug discovery and development.